title: [Hormone treatment of patients with breast carcinoma].
abstract: Endocrine treatments of breast cancer patients play an important role in the management of this common tumor of women. In this short review the most frequently applied drugs are discussed; thereafter, their use is shown in the curative (adjuvant) and in the palliative situation. In premenopausal women who suffer from a hormone-sensitive cancer, adjuvant treatments include either ovarian ablation or adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluoro-uracil. In post-menopausal women, the adjuvant treatment of choice is tamoxifen. The currently active protocols for adjuvant treatments of hormone-sensitive breast cancers of the International Breast Cancer Study Group (IBCSG) and the Swiss Group for Clinical Cancer Research (SAKK) should not be followed because of the anthracyclines administered to a high percentage of the involved patients. These drugs, known for their cardiotoxic side effects, have for the time being no place in the adjuvant treatment of hormone-sensitive breast cancers; therefore, the duty of the primary-care physician is to protect his patients from these protocols. In the palliative treatment, tamoxifen is the first choice. The success of this treatment is shown by a few examples.
authors.affiliation: Departement für Innere Medizin, Universitätsspital Zürich.
authors.forename: C
authors.initials: C
authors.lastname: Sauter
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D010166:Palliative Care; D013629:Tamoxifen / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D006728:Hormones; D013629:Tamoxifen